Unnamed: 0,title,date,stock,sentiment
1180377.0,"UPDATE: Sorrento Therapeutics Says COVIDTRAP 'binds strongly to the spike protein of the SARS-CoV-2 virus,' neutralizes the SARS-CoV-2 virus and prevents infection in African green monkey kidney epithelial cells in vitro at low concentration'",2020-06-05 09:31:00-04:00,SRNE,positive
1180378.0,Sorrento Therapeutics shares are trading higher after the company reportedly announced its STI-4398 demonstrated ability in preclinical studies to completely inhibit the Sars-Cov-2 viral infection in vitro.,2020-06-05 09:27:00-04:00,SRNE,positive
1180379.0,Sorento Therapeutics Say Company's STI-4398 Demonstrates Ability In Preclinical Studies To Completely Inhibit Sars-Cov-2 Viral Infection In Vitro,2020-06-05 09:07:00-04:00,SRNE,negative
1180380.0,Sorrento Therapeutics shares are trading higher after the company received FDA IND clearance to initiate the Phase I clinical trial of its CD38 antibody-drug conjugate STI-6129 for patients with amyloidosis.,2020-05-26 09:30:00-04:00,SRNE,positive
1180381.0,Sorrento Receives FDA IND Clearance To Initiate Phase I Clinical Trial Of Its CD38 Antibody-Drug Conjugate (ADC) STI-6129 For Patients With Amyloidosis,2020-05-26 09:00:00-04:00,SRNE,neutral
1180382.0,"Dawson James Initiates Coverage On Sorrento Therapeutics with Buy Rating, Announces Price Target of $24",2020-05-26 08:33:00-04:00,SRNE,neutral
1180383.0,"Hearing Dawson James Initiates Sorrento Therapeutics With Buy, Announces $24 Price Target",2020-05-26 08:05:00-04:00,SRNE,neutral
1180384.0,Dow Jones Market Talk Article Titled 'Sorrento's Coronavirus Drug Offers a Big Opportunity' Discusses Buy Recommendation On Stock From Dawson James Securities?,2020-05-26 07:56:00-04:00,SRNE,positive
1180385.0,Hindenburg Research Says 'The $SRNE CEO walked back his comments about having a cure moments ago We believe this amounts to flagrant securities fraud when compared to his statements to Fox last week. We encourage regulators to investigate any stock sales,2020-05-22 13:32:00-04:00,SRNE,positive
1180386.0,Sorento Shares Dropping Lower After Hindenburg Research Tweets Out CEO Comments,2020-05-22 13:31:00-04:00,SRNE,neutral
1180387.0,Sorrento Therapeutics Shares On Watch As Traders Circulate Thursday WealthWise Podcast With Doctors From Co.,2020-05-22 11:24:00-04:00,SRNE,positive
1180388.0,Sorrento Therapeutics shares are trading lower on continued weakness following a Wednesday short report.,2020-05-21 12:37:00-04:00,SRNE,negative
1180389.0,Sorrento Enters Binding Term Sheet To Buy Exclusive Rights To Abivertinib With Completed Registrational Trial Data In Non-Small Cell Lung Cancer,2020-05-21 07:02:00-04:00,SRNE,negative
1180390.0,Sorrento Shares Ticking Lower As Viceroy Tweets Short Position,2020-05-20 11:14:00-04:00,SRNE,neutral
1180391.0,Sorrento Therapeutics Shares Down 15%; Short Seller Hindenburg Research Publishes 'Sorrento's Pandemic Profiteering: Experts and Former Employees Speak Out on Sensational Claims of Covid-19 Cure',2020-05-20 09:42:00-04:00,SRNE,positive
1180392.0,"Sorrento Therapeutics Shares Halted On Circuit Breaker, Down Sharply From Session High But Still Up 27.5% For Session",2020-05-18 09:38:00-04:00,SRNE,positive
1180393.0,"STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies",2020-05-15 11:01:00-04:00,SRNE,negative
1180394.0,"'Reports that $SRNE has something against Covid will gun the stock, please be careful.. very small cap' -Tweet From Jim Cramer",2020-05-15 09:17:00-04:00,SRNE,neutral
1180395.0,Sorrento Therapeutics shares are trading higher amid investor attention surrounding the company's STI-1499 coronavirus antibody.,2020-05-15 09:13:00-04:00,SRNE,positive
1180396.0,"Sorrento Therapeutics Says Coronavirus Antibody STI-1499 Showed Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies, Indicates Potentially Strong Antibody Drug Candidate",2020-05-15 09:03:00-04:00,SRNE,positive
1180397.0,'California biopharmaceutical company claims coronavirus antibody breakthrough' -FOX News,2020-05-15 08:55:00-04:00,SRNE,neutral
1180398.0,Shares of several healthcare companies are trading higher after US unemployment figures came in below consensus estimates. Equities have been strong this week amid a rebound in oil prices and some US states easing lockdown restrictions.,2020-05-08 10:56:00-04:00,SRNE,positive
1180399.0,Sorrento Press Release Confirms Partnership With Mount Sinai,2020-05-08 09:26:00-04:00,SRNE,neutral
1180400.0,UPDATE: Sorrento Sees Beginning Phase 1 Trials Of Antibody Therapy To Potentially Treat Coronavirus In Q3'20,2020-05-08 09:13:00-04:00,SRNE,positive
1180401.0,Sorrento Therapeutics Reports Partnership With Mount Sinai Health To Jointly Develop Covi-Shield Antibody Therapy Against Coronavirus,2020-05-08 09:13:00-04:00,SRNE,neutral
1180402.0,Sorrento Therapeutics Filing Shows Registration For $250M Common Stock Shelf Offering,2020-04-27 16:41:00-04:00,SRNE,neutral
1180403.0,Sorrento To Provide Manufacturing Support To Celularity As CYNT-001 NK Cell Trial For Coronavirus Begins Enrolling Patients,2020-04-02 12:35:00-04:00,SRNE,positive
1180404.0,Sorrento And The University Of Texas Medical Branch At Galveston Enter Into Preclinical Testing Agreement For Coronavirus Therapeutic Candidates,2020-03-31 14:04:00-04:00,SRNE,positive
1180405.0,"Sorrento Therapeutics Announces On March 31, Co & Nanjing Hongjing Enterprise Management Consulting Co. Entered Into Binding Term Sheet;  Co To Sell To Nanjing Hongjing Certain Assets Related To Company's Operations In China, Nanjing Hongjing To Pay $30M",2020-03-31 06:49:00-04:00,SRNE,positive
1180406.0,"H.C. Wainwright Reiterates Buy on Sorrento Therapeutics, Lowers Price Target to $24",2020-03-30 07:15:00-04:00,SRNE,negative
1180407.0,"UPDATE: Sorrento Says Is In Active Talks With FDA's Center For Biologics Evaluation, Research To Gain Guidance On Rapid Development Of Novel Vaccine",2020-03-25 10:03:00-04:00,SRNE,positive
1180408.0,UPDATE: Sorrento Says 'STI-6991 is an I-CellTM COVID-19 cellular vaccine made of replication-deficient human erythroleukemia K562 cells expressing membrane-bound S1 protein of the SARS-CoV-2 virus',2020-03-25 10:03:00-04:00,SRNE,neutral
1180409.0,Sorrento Therapeutics Highlights Launch Of Novel I-Cell Coronavirus Cellular Vaccine Program,2020-03-25 10:02:00-04:00,SRNE,positive
1180410.0,"Sorrento Therapeutics Reports Collaboration With Mabpharm On Development, Commercialization Of ACE-MAB To Potentially Treat Coronavirus",2020-03-24 09:38:00-04:00,SRNE,positive
1180411.0,Sorrento Therapeutics Reports Collaboration With SmartPharm To Develop Gene-Encoded Antibody Vaccine Intended To Protect Against Coronavirus,2020-03-23 09:37:00-04:00,SRNE,positive
1180412.0,"Sorrento Therapeutics Reports Development Of 'COVIDTRAP Protein' For Potential Prevention, Treatment Of Coronavirus Disease",2020-03-20 07:10:00-04:00,SRNE,neutral
1180413.0,Sorrento Therapeutics Shares Were Volatile Around 2 p.m. EST Around Time Of Disclosure Of 40K Share Buy By Director Robin Smith,2020-03-05 15:53:00-05:00,SRNE,positive
1180414.0,Sorrento Therapeutics shares are trading higher as traders circulate bullish blog post suggesting a possible coronavirus play.,2020-03-05 12:01:00-05:00,SRNE,positive
1180415.0,"Sorrento Therapeutics Shares Spike To Session High, Now Up 10%, Amid Circulation Of Seeking Alpha Blog Post From Tues. 'Covid-19 Virus Spreads, Sorrento Therapeutics Stock Is A Buy Say Analysts Offering 1000% Upside'",2020-03-05 11:05:00-05:00,SRNE,positive
1180416.0,Sorrento Therapeutics Highlights Presentation Of Interim Results Of Phase 1b RTX In Cancer Pain Trial,2020-02-27 15:36:00-05:00,SRNE,negative
1180417.0,"Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, At LEERINK Global Healthcare Conference",2020-02-27 08:05:00-05:00,SRNE,neutral
1180418.0,Sorrento Therapeutics Files For 2M Share Offering Of Common Stock By Selling Shareholders,2020-01-29 16:56:00-05:00,SRNE,positive
1180419.0,Sorrento And Celularity To Initiate Emergency Allogeneic Natural Killer Cell Therapy Development For Coronavirus Infection,2020-01-29 07:07:00-05:00,SRNE,negative
1180420.0,Sorrento Therapeutics shares are trading lower after the company's board rejected a private equity offer of $7 per share to acquire the company.,2020-01-27 13:39:00-05:00,SRNE,negative
1180421.0,Sorrento's Board Rejects the Private Equity $7/Share Acquisition Offer,2020-01-27 07:06:00-05:00,SRNE,negative
1180422.0,"Sorrento Therapeutics shares are trading lower, reversing from Friday strength following an acquisition proposal from a private equity firm for $7/share.",2020-01-13 09:21:00-05:00,SRNE,positive
1180423.0,"Benzinga Pro's Top 5 Stocks To Watch For Fri., Jan. 10, 2020: LLY, JPM, SRNE, ELAN, TWTR",2020-01-10 09:03:00-05:00,SRNE,positive
1180424.0,Sorrento Therapeutics shares are trading higher after the company announced it has received a non-binding acquisition proposal from a private equity fund for $7 per share.,2020-01-10 07:41:00-05:00,SRNE,positive
1180425.0,Sorrento Therapeutics  Reports Received Non-Binding Acquisition Proposal At $7/Share,2020-01-10 07:00:00-05:00,SRNE,neutral
1180426.0,Sorrento Therapeutics Files for a New Drug Application for the Infliximab Biosimilar Antibody in China,2020-01-06 07:04:00-05:00,SRNE,neutral
1180427.0,Sorrento Therapeutics shares are trading lower. Not currently seeing any company-specific news.,2019-12-20 10:07:00-05:00,SRNE,neutral
1180428.0,Sorrento Therapeutics shares are trading higher. Not currently seeing any company-specific news.,2019-12-11 11:50:00-05:00,SRNE,positive
1180429.0,Sorrento Therapeutics shares are trading higher after the company announced a change in board members.,2019-12-09 13:21:00-05:00,SRNE,positive
1180430.0,Sorrento Therapeutics shares are trading lower as a potential sell-off after the stock increased roughly 135% since November 22.,2019-12-05 12:36:00-05:00,SRNE,positive
1180431.0,Sorrento Therapeutics shares are trading higher. Not seeing any news to justify the price action. NOTE: The stock is trading on above-average volume.,2019-12-03 10:36:00-05:00,SRNE,positive
1180432.0,Sorrento Therapeutics shares are trading higher. Not seeing any news to justify the price action.,2019-12-02 11:54:00-05:00,SRNE,positive
1180433.0,Sorrento Therapeutics shares are trading lower. Not seeing any news to justify the price action.,2019-11-27 09:49:00-05:00,SRNE,neutral
1180434.0,"Sorrento Therapeutics shares are trading higher after the company announced it has recieved and rejected an unsolicited, all cash proposal from two biopharmaceutical companies between $3-$5 per share in cash.",2019-11-25 07:50:00-05:00,SRNE,neutral
1180435.0,Sorrento Therapeutics Shares To Resume Trade At 7:30 a.m. EST,2019-11-25 07:08:00-05:00,SRNE,positive
1180436.0,"Sorrento Therapeutics Shares Halted to Announce Co. Received, Rejected Unsolicited All-Cash Proposal From 2 Biopharma Cos. Between $3-$5/Share In Cash",2019-11-25 07:08:00-05:00,SRNE,negative
1180437.0,Sorrento Therapeutics shares are trading higher despite no company-specific news. This could potentially be a rebound after the stock dropped approximately 35% over the past 7 trading sessions.,2019-10-16 15:01:00-04:00,SRNE,positive
1180438.0,Sorrento Therapeutics Announces $25M Registered Direct Offering; ~10.87M Shares At $2.30/Share And Related Warrant,2019-10-07 14:35:00-04:00,SRNE,positive
1180439.0,"JMP Securities Initiates Coverage On Sorrento Therapeutics with Market Outperform Rating, Announces $21 Price Target",2019-10-07 07:24:00-04:00,SRNE,positive
1180440.0,Sorrento Therapeutics Subsidiary Scilex Files an S-1 to the SEC for its Proposed IPO,2019-09-23 07:19:00-04:00,SRNE,neutral
1180441.0,Sorrento Therapeutics Prices 8.333M Shares At $3/Share,2019-06-28 08:39:00-04:00,SRNE,positive
1180442.0,Sorrento Therapeutics shares are trading lower after the company reported an offering of common stock and warrants.,2019-06-28 08:13:00-04:00,SRNE,neutral
1180443.0,UPDATE: Sorrento Says 'All dose groups had treatment effect size traditionally considered sufficient for approval by Regulators.',2019-06-19 07:08:00-04:00,SRNE,positive
1180444.0,Sorrento Therapeutics Offers Updates On Results Of Phase 1b RTX In Knee Osteoarthritis Pain Trial,2019-06-19 07:08:00-04:00,SRNE,negative
1180445.0,"Sorrento Therapeutics Offers Updates On CD38 Immunotherapies, Implementation Of Disruptive GMP Manufacturing For Off The Shell Cell Therapy",2019-06-19 07:07:00-04:00,SRNE,negative
1180446.0,Sorrento Therapeutics S-3 Shows Registration For ~1.33M Share Common Stock Offering Via Selling Shareholders,2019-06-17 16:33:00-04:00,SRNE,positive
1180447.0,Sorrento To Explore Potential Initial Public Offering Of Scilex Holding Company,2019-06-12 07:05:00-04:00,SRNE,neutral
1180448.0,Sorrento Therapeutics Reports Acceleration Of Human Investigational New Drug Filing Of Resiniferatoxin For Prolonged Non-Opioid Control Of Post-Amputation Neuropathic Pain,2019-06-10 07:20:00-04:00,SRNE,negative
1180449.0,"Sorrento Therapeutics Reports May ZTlido Sales $3.3M, Up From $2.4M In April; Says SP-102 Pivotal Phase 3 Trial Remains On Track For Completion In First Half Of 2020",2019-06-05 07:08:00-04:00,SRNE,neutral
1180450.0,Sorrento Therapeutics shares are higher after the company announced a global joint venture and commercial strategic partnership in China for its cannabidiol formulation technologies.,2019-06-04 09:21:00-04:00,SRNE,positive
1180451.0,Sorrento Announces Cannabidiol (CBD) Global Joint Ventures And Commercial Strategic Partnerships,2019-06-04 07:03:00-04:00,SRNE,neutral
1180452.0,Sorrento Therapeutics Establishes New Business Unit To Focus On Water-Soluble CBD Formulation Technology,2019-04-16 09:05:00-04:00,SRNE,neutral
1180453.0,Sorrento Therapeutics shares are trading higher after the company announced positive topline results in a discovery trial of a potential non-dopaminergic approach to controlling Parkinson's motor symptoms with Resiniferatoxin Intrathecal Administration.,2019-04-10 10:19:00-04:00,SRNE,positive
1180454.0,"Sorrento Therapeutics Announces Discovery Of A Potential Non-Dopaminergic Approach To Controlling Parkinson's Motor Symptoms With Resiniferatoxin Intrathecal Administration, Announces 'Positive And Better Than Initially Hoped For' Top Line Results",2019-04-10 09:04:00-04:00,SRNE,positive
1180455.0,"Patrick Soon-Shiong Says Lawsuit By Sorrento Therapeutics Is 'Without Merit', Intends To Defend It",2019-04-03 15:55:00-04:00,SRNE,negative
1180456.0,"Sorrento Therapeutics shares are trading higher after the company filed legal actions against Patrick Soon-Shiong, asserting claims for fraud and breach of contract regarding his purchase of the drug Cynviloq.",2019-04-03 12:41:00-04:00,SRNE,negative
1180457.0,"Sorrento Therapeutics 8-K Shows Co. Filed 2 Legal Actions Against Patrick Soon-Shiong And Entities Controlled By Him Asserting Claims For Fraud, Breach Of Contract Following Purchase Of Cynviloq In May 2015",2019-04-03 09:17:00-04:00,SRNE,negative
1180458.0,"Top 15 Most-Volatile Stocks For Fri., Mar. 29, 2019 Via Benzinga's Securities Lending Volatility Index Powered By Tidal Markets",2019-03-29 09:32:00-04:00,SRNE,positive
1180459.0,"Sorrento Therapeutics shares are trading lower in a potential sell off following recent strength. The company recently presented at Oppenheimer's healthcare conference and on Tuesday, its subsidiary Scilex Holdings published positive Phase 2 results.",2019-03-27 11:09:00-04:00,SRNE,positive
1180460.0,Sorrento Therapeutics shares are trading higher after the company reported its majority-owned subsidiary Scilex published positive results for its Phase 2 trial of SP-100 and is proceeding as planned with a Phase 3 study.,2019-03-26 09:17:00-04:00,SRNE,positive
1180461.0,"Sorrento Says Scilex's SP-102 Phase 3 Trial Is Proceeding As Planned, Has Reached Near 50% Enrollment Completion",2019-03-26 08:33:00-04:00,SRNE,positive
1180462.0,Sorrento Therapeutics Reports Its Majority-Owned Subsidiary Scilex Holdings Published Results Of Phase 2 Trial For SP-102 In Patients With Sciatica: 'All subjects experienced rapid reduction of leg and back pain...',2019-03-26 08:33:00-04:00,SRNE,neutral
1180463.0,"Top 15 Most-Volatile Stocks For Tues., Mar. 26, 2019 Via Benzinga's Securities Lending Volatility Index Powered By Tidal Markets",2019-03-26 08:22:00-04:00,SRNE,positive
1180464.0,Sorrento Therapeutics shares are trading lower as the stock pulls back from a 155% climb in price last week.,2019-03-25 08:25:00-04:00,SRNE,neutral
1180465.0,Sorrento Therapeutics shares are trading higher after the company announced the merger of Scilex and Semnur.,2019-03-22 09:40:00-04:00,SRNE,positive
1180466.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 22, 2019",2019-03-22 09:23:00-04:00,SRNE,positive
1180467.0,Sorrento Therapeutics shares are trading higher after the company presented at Oppenheimer's healthcare conference in New York on Wednesday.,2019-03-21 10:01:00-04:00,SRNE,positive
1180468.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Wed., Mar. 20, 2019",2019-03-20 09:36:00-04:00,SRNE,positive
1180469.0,B. Riley Maintains Buy On Sorrento Therapeutics And Raises Price Target From $10.50 To $12/Share; Firm Cites 'Numerous Catalysts' With High-Value/Late-Stage Candidates,2019-03-20 09:33:00-04:00,SRNE,neutral
1180470.0,Sorrento Therapeutics shares are trading higher ahead of the company's Wednesday presentation at Oppenheimer's healthcare conference in New York.,2019-03-19 12:27:00-04:00,SRNE,positive
1180471.0,Sorrento Therapeutics Filing Shows Registration For $100M Common Stock Offering,2019-03-15 07:00:00-04:00,SRNE,neutral
1180472.0,Sorrento Therapeutics Will Not Conduct a Phase 2 Study with Yuhan of Anti-PD-L1 Antibody IMC-001,2019-03-11 07:11:00-04:00,SRNE,neutral
1180473.0,Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With 'Positive' Therapeutic Signal And Absence Of Dose Limiting Toxicities,2019-01-22 07:12:00-05:00,SRNE,negative
1180474.0,Sorrento Therapeutics Reports Anti-CEA CAR-T Showed Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases,2018-11-06 08:07:00-05:00,SRNE,negative
1180475.0,Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma,2018-11-01 07:33:00-04:00,SRNE,neutral
1180476.0,Sorrento Therapeutics Shares Down 4%; Mox Reports Recently Tweeted 'short $SRNE',2018-10-03 10:45:00-04:00,SRNE,positive
1180477.0,Sorrento Therapeutics shares are up 7.6% after the company earlier announced its Scilex Pharmaceuticals Inc has received $140 million in royalty-based financing to support the commercialization of ZTlido pain medication.,2018-09-10 10:16:00-04:00,SRNE,positive
1180478.0,Sorrento Announces 1st Patient Treated for Osteoarthritis Knee Pain in Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations,2018-08-13 04:27:00-04:00,SRNE,negative
1180479.0,"Sorrento Acquires the Sofusa Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics, Terms Not Disclosed",2018-07-03 09:30:00-04:00,SRNE,neutral
1180480.0,"B. Riley FBR Initiates Coverage On Sorrento Therapeutics with Buy Rating, Announces $14.25 Price Target",2018-06-28 08:16:00-04:00,SRNE,neutral
1180481.0,"Sorrento Therapeutics Files for Resale of 1,381,345 Shares by Selling Shareholders",2018-05-11 06:17:00-04:00,SRNE,positive
1180482.0,"Sorrento Therapeutics Files for  Resale of 34,159,77 Shares by Selling Shareholders",2018-05-11 06:15:00-04:00,SRNE,positive
1180483.0,Sorrento Therapeutics And Celularity Begin Anti-CD38 CAR-T Phase 1 Clinical Trial,2018-04-05 14:59:00-04:00,SRNE,neutral
1180484.0,Sorrento Therapeutics Shares Dip To Session Lows As Traders Circulate SeekingAlpha Article From J Capital Suggesting Stock Is 'A Zero',2018-03-27 11:40:00-04:00,SRNE,positive
1180485.0,Sorrento Therapeutics Announces join Shao CFO,2018-03-19 08:10:00-04:00,SRNE,positive
1180486.0,"Benzinga Pro's Top 10 Most-Searched Tickers During The Morning Of Thurs., Mar. 1",2018-03-01 08:56:00-05:00,SRNE,positive
1180487.0,"UPDATE: HC Wainwright Values Sorrento's Celularity Stake At $1.4B, ZTlido At $1.3B, Up From $800M Prior To Approval",2018-02-28 15:48:00-05:00,SRNE,positive
1180488.0,UPDATE: HC Wainwright On Sorrento Says Modeling For Peak ZTlido US Sales $1B+ By '25,2018-02-28 15:47:00-05:00,SRNE,neutral
1180489.0,"Sorrento Shares At Session Highs, Now Up 17%; HC Wainwright Recently Issued Mid-Day Note Setting $38 Price Target On Stock, Reiterating Buy Rating",2018-02-28 15:46:00-05:00,SRNE,positive
1180490.0,"Sorrento Therapeutics Shares Resume Trade, Now Up 3.4% For Session",2018-02-28 14:49:00-05:00,SRNE,positive
1180491.0,Sorrento Therapeutics Shares To Resume Trade At 2:45 p.m. EST,2018-02-28 14:40:00-05:00,SRNE,positive
1180492.0,UPDATE: Sorrento Therapeutics Says It Will Explore Expansion Of  ZTlido Into Additional Indications And The Underlining Platform Tech Of ZTlido FOr Other APIs And Combination Of APIs,2018-02-28 14:13:00-05:00,SRNE,neutral
1180493.0,"Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido 1.8% for PHN Pain",2018-02-28 14:12:00-05:00,SRNE,negative
1180494.0,Sorrento Therapeutics Shares Halted News Pending,2018-02-28 14:09:00-05:00,SRNE,positive
1180495.0,Earlier Form 4 Filing Shows Sorrento Therapeutics 10% Owner Ally Bridge Group Sold 662.912K Shares At Avg. Prices Ranging From $6.75 to $7.19,2018-02-08 10:59:00-05:00,SRNE,positive
1180496.0,Sorrento's JV ImmuneOncia Receives Approval To Begin Trial Of Anti-PD-L1 Monoclonal Antibody In South Korea,2018-02-05 08:12:00-05:00,SRNE,positive
1180497.0,"Sorrento's and Yuhan's Joint Venture, ImmuneOncia, Receives Approval to Begin clinical trial of Anti-PD-L1 Monoclonal Antibody in South Korea",2018-02-05 08:08:00-05:00,SRNE,positive
1180498.0,Sorrento Therapeutics Issues Letter To Shareholders,2018-02-05 08:07:00-05:00,SRNE,neutral
1180499.0,"Sorrento Therapeutics Shares Make Mid-Day Parabolic Move, Spike ~$0.40 High Then Quickly Give Up Near-Term Gains; Traders Circulated Vague Chatter In Name",2018-01-23 10:25:00-05:00,SRNE,positive
1180500.0,"HC Wainwright Analyst Raghuram Selvaraju Believes 'Juno Acquisition Bodes Well For Sorrento'; Reiterated Buy Rating, $30 Price Target",2018-01-23 07:15:00-05:00,SRNE,positive
1180501.0,"Sorrento Therapeutics Shares Closed Mon. Up 21%; Form 4 Shows Pres, CEO Henry Ji Purchased ~1.8M Shares On Jan. 21",2018-01-23 07:14:00-05:00,SRNE,positive
1180502.0,"Sorrento Therapeutics Shares Continuing Higher Wed., Up 7.8%, Following 16% Rally On Tues.; Stock Up ~140% Since Mid Dec.; Have Not Seen News To Justify Price Action, But Important To Note Price Moved Over 2 Important Technical Levels At $5, $6",2018-01-17 09:22:00-05:00,SRNE,positive
1180503.0,"Sorrento Therapeutics Shares Up 13.81%; Earlier Co. Announced CEO Henry JI To Present ""Game-Changer"" CAR-T Tech At East/West CEO Conference Saturday Jan. 6th",2018-01-02 14:05:00-05:00,SRNE,positive
1180504.0,Sorrento Therapeutics 8-K Shows Co. Entered Securities Purchase Deal With Accredited Invesotrs For $50M In Promissory Notes,2017-12-11 09:33:00-05:00,SRNE,positive
1180505.0,Sorrento Therapeutics S-3 Filing Shows Registration For $350M Mixed Securities Offering,2017-11-09 09:16:00-05:00,SRNE,positive
1180506.0,"FDA Acknowledges Receipt Of Sorrento Therapeutics Inc, NDA For ZTlido, PDUFA Date Set For February 28, 2018",2017-09-12 06:07:00-04:00,SRNE,neutral
1180507.0,"Oppenheimer Initiates Coverage On Sorrento Therapeutics with Outperform Rating, Announces $7.00 Price Target",2017-08-04 08:06:00-04:00,SRNE,neutral
1180508.0,"Companies Holding Shareholder Meetings Today Include: Greenhilll & Co, McKesson, MGIC Investment, Newtek, Riverview Bancorp, Sorrento Therapeutics, and Thermon Group",2017-07-26 08:43:00-04:00,SRNE,neutral
1180509.0,Sorrento Therapeutics Announces FDA Authorization of IND To Begin Trial of RTX,2017-06-29 12:27:00-04:00,SRNE,neutral
1180510.0,Sorrento Therapeutics Subsidiary Semnur Pharma Gives Update on 'Successful' Phase 1/2 Trial,2017-06-26 07:04:00-04:00,SRNE,neutral
1180511.0,Sorrento Therapeutics Reports Dismissal of Suits,2017-06-14 14:31:00-04:00,SRNE,neutral
1180512.0,Sorrento Therapeutics Subsidiary SCILEX Announces Positive Data In Comparative Adhesion Performance Study,2017-06-14 09:01:00-04:00,SRNE,positive
1180513.0,White Diamond Research Analyst Adam Gefvert Tweets: Just got news that the CFO of $SRNE is leaving. The company told me when I tried to reach investor relations. Seems bearish.,2017-05-19 15:49:00-04:00,SRNE,positive
1180514.0,Sorrento Therapeutics Reports the Completion of GMP Manufacturing Plant in Suzhou,2017-05-04 10:19:00-04:00,SRNE,neutral
1180515.0,Sorrento Therapeutics Prices Offering of 23.625M Shares at $2/Share,2017-04-13 10:00:00-04:00,SRNE,positive
1180516.0,Sorrento Reports Proposed Public Offering of Common Stock,2017-04-12 16:00:00-04:00,SRNE,neutral
1180517.0,"Sorrento, Wildcat Capital Announce Resolution To Wildcat's Claims Seeking Inspection Of Documents Related To Company's Private Placement Agreements",2017-03-20 08:09:00-04:00,SRNE,positive
1180518.0,Sorrento Says Endpoints Met in European Union Pivotal Bioequivalence Clinical Study for ZTlido,2017-01-09 09:10:00-05:00,SRNE,neutral
1180519.0,Roth Capital Initiates Coverage on Sorrento Therapeutics at Buy,2016-10-03 08:31:00-04:00,SRNE,neutral
1180520.0,"Rodman & Renshaw Maintains Buy on Sorrento Therapeutics, Lowers PT to $30.00",2016-04-05 07:29:00-04:00,SRNE,negative
1180521.0,"Rodman & Renshaw Maintains Buy on Sorrento Therapeutics, Lowers PT to $40.00",2016-02-29 07:14:00-05:00,SRNE,negative
1180522.0,"FBR Capital Initiates Coverage on Sorrento Therapeutics at Outperform, Announces $22.00 PT",2015-12-22 07:55:00-05:00,SRNE,neutral
1180523.0,"H.C. Wainwright Assumes Sorrento Therapeutics at Buy, Announces $45.00 PT; Says Firm Is 'emerging biopharma' With 'Best In Class'  Cell Based Immunotherapy Approach",2015-12-07 07:12:00-05:00,SRNE,positive
1180524.0,"Brean Capital Initiates Coverage on Sorrento Therapeutics at Buy, Announces $17.00 PT",2015-05-28 06:30:00-04:00,SRNE,neutral
1180525.0,"Advaxis, Sorrento Announces Collaboration",2015-05-19 07:32:00-04:00,SRNE,neutral
1180526.0,Sorrento Acquires South American Rights to Cynviloq,2015-05-01 13:17:00-04:00,SRNE,neutral
1180527.0,"Sorrento, Conkwest Announce Exclusive Global Collaboration",2014-12-19 06:02:00-05:00,SRNE,positive
1180528.0,Sorrento Awarded Up To $2.6M From Government For Development of New Ati Bacterial Antibodies,2014-07-01 08:45:00-04:00,SRNE,positive
1180529.0,Morphotek and Sorrento Sign Research Agreement for Morphotek Antibody Drug Conjugates,2014-06-25 08:46:00-04:00,SRNE,positive
1180530.0,Sorrento Announces Filing of S-1 For Potential IPO for Subsidiary Ark Animal Health,2014-06-23 08:46:00-04:00,SRNE,neutral
1180531.0,UPDATE: MLV & Co. Initiates Coverage On Sorrento Therapeutics On Good Cynviloq Potential,2014-06-19 07:57:00-04:00,SRNE,positive
1180532.0,Afternoon Market Movers,2014-05-15 15:53:00-04:00,SRNE,neutral
1180533.0,Stocks Hitting 52-Week Lows,2014-05-15 10:33:00-04:00,SRNE,negative
1180534.0,Morning Market Losers ,2014-05-15 09:47:00-04:00,SRNE,negative
1180535.0,UPDATE: Sorrento Therapeutics Shares Fall 30% Premarket Following Pricing of Offering at $5.25/Share,2014-05-15 07:29:00-04:00,SRNE,positive
1180536.0,"US Stock Futures Flat Ahead Of Economic Data, Wal-Mart Earnings",2014-05-15 07:15:00-04:00,SRNE,neutral
1180537.0,Sorrento Therapeutics Prices 4.765M Share IPO at $5.25/Share,2014-05-15 05:31:00-04:00,SRNE,positive
1180538.0,"Sorrento Announces Offering, No Details Disclosed",2014-05-14 16:41:00-04:00,SRNE,negative
1180539.0,Sorrento Announces Transfer of Orphan Drug Designation for Intrathecal Resiniferatoxin from NIH,2014-05-13 07:36:00-04:00,SRNE,neutral
1180540.0,Sorrento Presents Positive Data from Clinical Study of Resiniferatoxin for Intractable Cancer Pain at ASRA Meeting ,2014-04-04 06:10:00-04:00,SRNE,negative
1180541.0,Sorrento Says Resiniferatoxin Appears Well-Tolerated With No Opioid-Like Toxicities,2014-04-04 06:08:00-04:00,SRNE,negative
1180542.0,Sorrento Announces First Patient Dosed in TRIBECA Trial ,2014-04-01 05:51:00-04:00,SRNE,neutral
1180543.0,Stocks Hitting 52-Week Lows,2013-12-19 10:33:00-05:00,SRNE,negative
1180544.0,OPKO Completes Sale of Sorrento Therapeutics Stake,2013-12-19 10:22:00-05:00,SRNE,neutral
1180545.0,UPDATE: Aegis Capital Initiates Coverage On Sorrento Therapeutics On RTX-100,2013-12-04 07:49:00-05:00,SRNE,neutral
1180546.0,Sorrento Therapeutics Adopts Stockholder Rights Plan,2013-11-12 08:12:00-05:00,SRNE,positive
1180547.0,US Stock Futures Flat Ahead Of Durable-Goods Data,2013-10-25 07:26:00-04:00,SRNE,neutral
1180548.0,"Sorrento Therapeutics Prices 4.15M Share Offering at $7,25/Share",2013-10-25 06:08:00-04:00,SRNE,positive
